Beta Bionics, Inc.: chief commercial officer Mark Hopman sold 775 shares

What happened Mark Hopman, chief commercial officer, sold 775 shares on Oct 14, 2026. The Form 4 reports a weighted average sale price of $17.35 and total proceeds of $13,446.

Key details

• Transaction date and prices: Oct 14, 2026; weighted average sale price $17.35; reported price range $17.35 to $18.3499.
• Shares sold and value: 775 shares sold for $13,446.
• Shares owned after the transaction: not reported in the filing.
• Footnotes: the sale was made pursuant to a Rule 10b5-1 plan adopted on Jun 10, 2026. The filing states that, upon request, full information about the number of shares sold at each separate price will be provided.
• Filing date: Oct 16, 2026 (no late filing flag indicated in the report).

Why it may matter The filing reports an open market/private sale executed under a 10b5-1 plan; it does not report an option exercise, gift, or tax-withholding event. A filing does not show why the insider traded or why the company acted.